Page last updated: 2024-12-05

sulfacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfacetamide is a sulfonamide antibiotic that is used topically to treat bacterial infections of the eye. It works by inhibiting the synthesis of folic acid, which is essential for bacterial growth. Sulfacetamide is typically applied as a solution, ointment, or eye drops. Its effects include reducing inflammation and redness, and helping to clear up bacterial infections. Sulfacetamide is important for treating bacterial conjunctivitis (pink eye), blepharitis (inflammation of the eyelids), and other eye infections. It is studied to understand its effectiveness in treating different types of bacterial infections and to develop new formulations for improved delivery and efficacy.'

Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8482
CHEMBL ID687
SCHEMBL ID359721
MeSH IDM0020737
PubMed CID5320
CHEMBL ID455
CHEBI ID63845
SCHEMBL ID40863
MeSH IDM0020737

Synonyms (311)

Synonym
STL308440
ENAMINE_001217
SDCCGMLS-0064665.P001
n-4-acetylsulfanilamide
brn 0746675
ai3-08023
n(sup 4)-acetylsulfanilamide
n(sup 4)-acetsulfanilamide
p-sulfamoylacetanilide
n-(4-sulfamylphenyl)acetamide
nsc 217
sulfanilamide-n(sup 4)-acetate
4'-sulphamoylacetanilide
ccris 6813
einecs 204-486-7
acetamide, n-(4-(aminosulfonyl)phenyl)-
n-(4-(aminosulfonyl)phenyl)acetamide
n'-acetylsulphanilamide
OPREA1_582774
nsc-406839
nsc406839
nsc-217
nsc217
p-sulfamylacetanilide
acetamide, n-[4-(aminosulfonyl)phenyl]-
p-(acetylamino)benzenesulfonamide
neotherapol
4-acetylaminobenzenesulfonamide
benzenesulfonamide, 4-(acetylamino)-
4'-sulfamoylacetanilide
acetanilide, 4'-sulfamoyl-
n-(4-sulphamoylphenyl)acetamide
sulfanilamide-n4-acetate
erytrin
n4-acetylsulfanilamide
121-61-9
4-acetamidobenzenesulfonamide
n-(4-sulfamoylphenyl)acetamide
p-acetamidobenzenesulfonamide
n4-acetsulfanilamide
acetylsulfanilamide
benzenesulfonamide, p-acetamido-
a-319
bdbm16643
chembl687 ,
aromatic sulfonamide compound 8
4-acetamido-benzenesulfonamide
OPREA1_094374
A0115
pkofbdhytmyvgj-uhfffaoysa-
inchi=1/c8h10n2o3s/c1-6(11)10-7-2-4-8(5-3-7)14(9,12)13/h2-5h,1h3,(h,10,11)(h2,9,12,13)
n4-acetyl metabolite
AKOS000141336
HMS1397H07
A18135
NCGC00248191-01
340484wz3l ,
unii-340484wz3l
4'-sulfamylacetanilide
NCGC00254753-01
dtxcid2021529
tox21_300850
cas-121-61-9
dtxsid4041529 ,
acetsulphanilamide
FT-0647475
sulfacetamide sodium impurity b [ep impurity]
n4-acetylsulfanilamide [mi]
acetylsulfanilamide, n4-
n-(4-sulfamoyl-phenyl)-acetamide
n-[4-(aminosulfonyl)phenyl]acetamide
n4 -acetylsulfanilamide
PS-4449
SCHEMBL359721
n-[4-(aminosulfonyl)phenyl]acetamide #
4-n-acetylaminophenylsulfonamide
cambridge id 5152132
W-108453
mfcd00035784
Z27682721
CS-0080221
EN300-15532
Q27256303
SY081511
n-[4-(aminosulf
HY-W069721
AC-7630
MLS001076499
KBIO1_000227
DIVK1C_000227
nsc63871
n-acetylsulfanilamide
formosulfacetamide
acetosulfamin
n-acetyl-4-aminobenzenesulfonamide
wln: zr dswmv1
sulphacetamide
sulfacetimide
acetamide, n-sulfanilyl-
n'-acetylsulfanilamide
n-acetylsulfanilamine
sulfacet
sulamyd
acetamide, n-[(4-aminophenyl)sulfonyl]-
nsc-63871
sulfanilacetamide
sulfacyl
alesten
sulfanilamide, n(sup 1)-acetyl-
n-sulfanilylacetamide
acetocid
steramide
region
n(sup 1)-acetyl-4-aminophenylsulfonamide
a-500
n(sup1)-acetylsulfanilamide
n-[(p-aminophenyl)sulfonyl]acetamide
urosulfone
urosulfon
p-aminobenzenesulfonacetamide
albucid
sulphasil
albamine
acetosulfamine
n-sulphanilylacetamide
oclucid
SPECTRUM_000984
PRESTWICK2_000014
OPREA1_810285
CBDIVE_013934
144-80-9
n-[(4-aminophenyl)sulfonyl]acetamide
n-(4-aminophenyl)sulfonylacetamide
sulfacetamide
sulfacetamide (usp/inn)
D05947
BSPBIO_000047
IDI1_000227
BPBIO1_000053
OPREA1_686524
SPECTRUM5_001230
PRESTWICK3_000014
BSPBIO_002773
CBCHROMO1_000180
NCGC00021857-03
sulfacetamidum [inn-latin]
sulfacyl (van)
bleph-10 liquifilm
sulphacetamidum
caswell no. 808a
nsc 63871
ccris 6273
solfacetamide [dcit]
op-sulfa 30
ophthel-s
sulfacetamida [inn-spanish]
einecs 205-640-6
epa pesticide chemical code 077904
ai3-26837
sebizon
n-((4-aminophenyl)sulfonyl)acetamide
brn 0981718
acetamide, n-((4-aminophenyl)sulfonyl)-
sulfanilazetamid [german]
n(sup 1)-acetylsulfanilamide
sulfacetamide, >=98.0%
DB00634
p-aminobenzenesulfonoacetamide
n-(p-aminobenzenesulfonyl)acetamide
n(1)-acetyl-4-aminophenylsulfonamide
n(1)-acetylsulfanilamide
n-((p-aminophenyl)sulfonyl)acetamide
NCGC00021857-05
NCGC00021857-04
fml-s
sulf-10
predamide
cetapred
sulster
bleph-10
MLS000069710 ,
smr000058173
KBIO2_006600
KBIO3_001993
KBIO2_004032
KBIO2_001464
KBIOSS_001464
KBIOGR_001691
SPECTRUM4_001146
SPECTRUM2_001318
NINDS_000227
PRESTWICK1_000014
NCIOPEN2_002838
SPBIO_001968
SPBIO_001415
SPECTRUM3_001017
PRESTWICK0_000014
SPECTRUM1500545
NCGC00018242-01
STK068185
HMS2092I13
sulfacetamidum
CHEMBL455 ,
triple sulfa (sulfacetamide)
chebi:63845 ,
sulfacetamide (triple sulfa)
HMS500L09
HMS1921A11
bdbm50316126
n-acetyl-4-amino-benzenesulfonamide
sulfacetamide, 1
NCGC00018242-04
AKOS000119729
NCGC00018242-05
NCGC00018242-02
NCGC00018242-08
NCGC00018242-06
NCGC00018242-07
NCGC00018242-03
HMS3259G06
dtxcid406060
dtxsid8026060 ,
cas-144-80-9
tox21_303100
NCGC00257159-01
NCGC00259548-01
tox21_201999
BBL012083
S0577
nsc757323
pharmakon1600-01500545
nsc-757323
tox21_110846
n1-acetylsulfanilamide
solfacetamide
sulfacetamida
sulfanilazetamid
HMS2232K07
CCG-39256
n-(4-aminobenzenesulfonyl)acetamide
sulfacetamide [usp:inn:ban]
unii-4965g3j0f5
4965g3j0f5 ,
4-14-00-02662 (beilstein handbook reference)
FT-0631838
sulfacetamide component of vagilia
sulfacetamide component of gyne-sulf
sultrin component sulfacetamide
triple sulfa (sulfacetamide) [orange book]
sulfacetamide [mi]
sulfacetamide [inn]
sulfacetamide component of trysul
vagilia component sulfacetamide
sulfacetamide [who-dd]
sulfacetamide [who-ip]
n-((4-aminophenyl)sulfonyl)acetamide [who-ip]
gyne-sulf component sulfacetamide
sulfacetamide [usp impurity]
trysul component sulfacetamide
sulfacetamide [mart.]
sulfadimidine impurity e [ep impurity]
sulfacetamide component of sultrin
sulfacetamide [orange book]
sulfacetamidum [who-ip latin]
sulfacetamide [vandf]
S5546
HMS3374O02
NC00538
SCHEMBL40863
tox21_110846_1
KS-5327
n-(4-aminophenylsulfonyl)acetamide
4-[(acetylamino)sulfonyl]aniline
4-[(acetylamino) sulfonyl]aniline
4-acetylaminosulfonylaniline
Q-201757
sulfacetamide, antibiotic for culture media use only
sulfanilamide, n1-acetyl-
AB00052094_14
OPERA_ID_1990
mfcd00066501
n-[(4-aminobenzene)sulfonyl]acetamide
sulfacetamide, >=98.0% (nt)
SR-01000000194-2
sr-01000000194
sulfacetamide, vetranal(tm), analytical standard
sulfacetamide, united states pharmacopeia (usp) reference standard
AC2473
sulfacetamide 100 microg/ml in acetonitrile
n-[(4-aminophenyl)sulfonyl]acetamide; sulfacetamide; sulfadimidine imp. e (pharmeuropa); sulfadimidine impurity e
SBI-0051519.P003
SY014752
CS-0013812
HY-N7123
Q2022983
BRD-K21520694-001-12-3
EN300-18138
gtpl12633
Z57202572
sulfadimidine impurity e (ep impurity)
sulfacetamide (mart.)
4-(acetylaminosulfonyl)aniline
n-(p-aminophenylsulfonyl)acetamide
sulfacetamide (usp:inn:ban)
d10af06
s01ab04
sulfacetamid
sulfacetamida (inn-spanish)
sulfacetamidum (inn-latin)
n-acetyl-4-aminobenzenesulfonic acid amide
sulfacetamide (usp impurity)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Some widely used ototopical preparations are potentially toxic to the middle and inner ear."( Ototoxicity of Vasocidin drops applied to the chinchilla middle ear.
Brown, OE; Masaki, M; Meyerhoff, WL; Wright, CG, 1988
)
0.27
" Only 7% of participants had treatment-related adverse events (AEs), mostly mild or moderate in severity."( Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
Del Rosso, JQ, 2010
)
0.36
" Results of HET-CAM and ICE tests suggest that sulphacetamide is moderately toxic in the presence of light/UV-A and very slightly irritant without irradiation."( Photochemical toxicity of drugs intended for ocular use.
Kaithwas, G; Kishor, K; Sahu, RK; Saraf, SA; Singh, B, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally."( Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Babu, YS; Bantia, S; Chand, P; Chu, N; Cole, LB; Kotian, PL; Laver, WG; Montgomery, JA; Pathak, VP; Petty, SL; Shrout, DP; Walsh, DA; Walsh, GM, 1997
)
0.3
" This principle is applied for the stability-indicating determination of sulfacetamide in the presence of sulfanilamide, sulfaquinoxaline in feed, and sulfabromomethazine in dosage forms."( Facile separation of sulfonamides from their degradates by liquid--liquid extraction.
Blodinger, J; Fink, DW; Martin, RP, 1978
)
0.49
" The method is applied to the determination of sulphacetamide in dosage forms."( Spectrophotometric determination of sulphacetamide.
Agrawal, YK; Girdhar, R; Jain, VK; Menon, SK,
)
0.13
" The analytical utility of method was checked by determining the SFA in various pharmacological dosage forms."( Carbon nanotube embedded poly 1,5-diaminonapthalene modified pyrolytic graphite sensor for the determination of sulfacetamide in pharmaceutical formulations.
Agrawal, B; Choubey, PK; Goyal, RN; Yadav, SK, 2014
)
0.61
" The suggested methods were validated in compliance with the ICH guidelines and were successfully applied to determine both drugs in their pure forms, laboratory prepared mixtures and dosage form."( Validated Chromatographic Methods for the Simultaneous Determination of Sulfacetamide Sodium and Prednisolone Acetate in their Ophthalmic Suspension.
AbdElHamid, G; El-Ragehy, NA; Hegazy, MA; Tawfik, SA, 2017
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
EC 2.5.1.15 (dihydropteroate synthase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
substituted aniline
N-sulfonylcarboxamideA mixed diacylamine resulting from the formal condensation of the nitrogen of a carboxamide with a sulphonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency8.91250.004023.8416100.0000AID485290
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
USP1 protein, partialHomo sapiens (human)Potency100.00000.031637.5844354.8130AID743255
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency0.12590.000221.22318,912.5098AID588516
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.63100.001318.074339.8107AID926; AID938
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.36490.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency2.81840.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.68320.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.60080.003041.611522,387.1992AID1159552; AID1159553
farnesoid X nuclear receptorHomo sapiens (human)Potency61.82590.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.94100.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency19.49380.001024.504861.6448AID743215
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency1.41250.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency1.12200.125912.234435.4813AID1458
TAR DNA-binding protein 43Homo sapiens (human)Potency1.00001.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki0.04900.00021.10439.9000AID254245
Carbonic anhydrase 1Homo sapiens (human)Ki11.25130.00001.372610.0000AID1797528; AID254242; AID50350
Carbonic anhydrase 2Homo sapiens (human)Ki4.20000.00000.72369.9200AID1797528; AID254243; AID47898
Carbonic anhydrase 5A, mitochondrialMus musculus (house mouse)Ki6.17700.00300.45603.0000AID1797528
Carbonic anhydrase 9Homo sapiens (human)Ki0.13500.00010.78749.9000AID254244
Carbonic anhydrase 4Bos taurus (cattle)Ki5.51160.00300.59349.6500AID1797528; AID48119
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)18.00000.00060.87267.3000AID472620
Dihydrofolate reductase Bos taurus (cattle)IC50 (µMol)22.00000.00170.04350.1007AID472619
Serum paraoxonase/arylesterase 1Homo sapiens (human)Ki86.00009.00009.00009.0000AID1799602
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)500.00000.01002.765610.0000AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (85)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductase Bos taurus (cattle)
response to methotrexateDihydrofolate reductase Bos taurus (cattle)
tetrahydrofolate metabolic processDihydrofolate reductase Bos taurus (cattle)
tetrahydrofolate biosynthetic processDihydrofolate reductase Bos taurus (cattle)
negative regulation of plasma lipoprotein oxidationSerum paraoxonase/arylesterase 1Homo sapiens (human)
cholesterol metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
response to toxic substanceSerum paraoxonase/arylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxSerum paraoxonase/arylesterase 1Homo sapiens (human)
carboxylic acid catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
organophosphate catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
phosphatidylcholine metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
lactone catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Bos taurus (cattle)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductase Bos taurus (cattle)
dihydrofolate reductase activityDihydrofolate reductase Bos taurus (cattle)
aryldialkylphosphatase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
arylesterase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
calcium ion bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
phospholipid bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
side of membraneCarbonic anhydrase 4Bos taurus (cattle)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytoplasmDihydrofolate reductase Bos taurus (cattle)
mitochondrionDihydrofolate reductase Bos taurus (cattle)
extracellular regionSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
endoplasmic reticulum membraneSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular exosomeSerum paraoxonase/arylesterase 1Homo sapiens (human)
blood microparticleSerum paraoxonase/arylesterase 1Homo sapiens (human)
high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
spherical high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (146)

Assay IDTitleYearJournalArticle
AID290102Inhibition of human AQP4b-mediated water transport in Xenopus oocytes at 20 uM2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Identification of arylsulfonamides as Aquaporin 4 inhibitors.
AID254243Inhibitory activity against human Carbonic anhydrase II (hCA II)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID254245Inhibitory activity against human Carbonic anhydrase XII (hCA XII)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID342472Inhibition of AQP4 in mouse erythrocytes assessed as inhibition of osmotic water permeability at 100 uM after 15 mins by stopped-flow light scattering method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID342471Inhibition of AQP4 in wild type mouse brain gilial cells assessed as reduction of osmotic equilibrium rate at 10 to 100 uM after 15 mins by calcein quenching assay relative to water permeability2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID1723490Antibacterial activity against Enterococcus faecium HM965 incubated for 18 to 20 hrs under aerobic condition by CLSI protocol based broth microdilution assay
AID50350Inhibition of cloned human cytosolic isozyme Carbonic anhydrase I2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID342466Inhibition of AQP4 expressed in rat FRT cells assessed as osmotic water permeability at 10 uM by stopped-flow light scattering method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID254244Inhibitory activity against human Carbonic anhydrase IX (hCA IX)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID147482In vitro inhibitory activity against H1N9 strain of Influenza neuraminidase (membrane) at 7 mM concentration1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID232688Selectivity ratio of KI, human carbonic anhydrase II (hCA II), to that of KI, mouse carbonic anhydrase V (mCA V)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID342468Inhibition of AQP4 expressed in rat FRT cells assessed as osmotic water permeability at 100 uM after 60 mins by stopped-flow light scattering method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID342470Inhibition of AQP4 in wild type mouse brain gilial cells assessed as osmotic water permeability at 10 to 100 uM after 15 mins by calcein quenching assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID48309Inhibition of murine mitochondrial isozyme Carbonic anhydrase V at 20 degrees C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID342469Inhibition of AQP4 expressed in rat FRT cells assessed as transepithelial osmotic water permeability at 100 uM by dye dilution method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID48119Inhibition of bovine membrane bound isozyme carbonic anhydrase IV isolated from microsomes at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID47898Inhibition of human cytosolic isozyme Carbonic anhydrase II at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID50169Inhibitory activity against bovine Carbonic anhydrase1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
The binding of benzenesulfonamides to carbonic anhydrase enzyme. A molecular mechanics study and quantitative structure-activity relationships.
AID342467Inhibition of AQP4 expressed in rat FRT cells assessed as osmotic water permeability at 100 uM after 15 mins by stopped-flow light scattering method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID254242Inhibitory activity against human Carbonic anhydrase I (hCA I)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1797528Esterase Assay from Article 10.1021/jm031057+: \\Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.\\2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1188546Antimicrobial activity against Pseudomonas aeruginosa assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID743579Antimicrobial activity against Escherichia coli at 100 ug after 24 hrs by agar disc diffusion method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID1188547Antimicrobial activity against Candida albicans assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID660264Ratio of MIC for wild type Escherichia coli HS414 to MIC for acrB-deficient Escherichia coli HS832 by agar dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID743576Antimicrobial activity against Staphylococcus aureus after 24 hrs by micro-dilution susceptibility method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1188544Antimicrobial activity against Bacillus subtilis assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID25817PKa value was measured1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID1188550Antimicrobial activity against Escherichia coli assessed as inhibition of visible growth after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID1188549Antimicrobial activity against Bacillus subtilis assessed as inhibition of visible growth after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID743585Antimicrobial activity against Staphylococcus aureus at 100 ug after 24 hrs by agar disc diffusion method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID289693Antibacterial activity against Pasteurella multocida at 30 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID1188552Antimicrobial activity against Candida albicans assessed as inhibition of visible growth after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID26539pKa value is evaluated; activity is unretained1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1188545Antimicrobial activity against Escherichia coli assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID743575Antimicrobial activity against Bacillus subtilis after 24 hrs by micro-dilution susceptibility method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID472619Inhibition of bovine DHFR after 2 mins2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID472624Antibacterial activity against Bacillus subtilis after 24 hrs by microdilution susceptibility method2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID743584Antimicrobial activity against Bacillus subtilis at 100 ug after 24 hrs by agar disc diffusion method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID670244Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Synthesis and antimycobacterial activity of some phthalimide derivatives.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID743577Antimicrobial activity against Pseudomonas aeruginosa at 100 ug after 24 hrs by agar disc diffusion method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID743574Antimicrobial activity against Micrococcus luteus after 24 hrs by micro-dilution susceptibility method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID472635Antibacterial activity against Staphylococcus aureus at 100 ug/disk after 24 hrs by disk diffusion method2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1188548Antimicrobial activity against Staphylococcus aureus assessed as inhibition of visible growth after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID743572Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs by micro-dilution susceptibility method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID743581Antimicrobial activity against Micrococcus luteus at 100 ug after 24 hrs by agar disc diffusion method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID472623Antibacterial activity against Bacillus subtilis at 200 ug/disk after 24 hrs by disk diffusion method2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID743573Antimicrobial activity against Escherichia coli after 24 hrs by micro-dilution susceptibility method2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID472636Antibacterial activity against Bacillus subtilis at 100 ug/disk after 24 hrs by disk diffusion method2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID64418Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.41983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1188543Antimicrobial activity against Staphylococcus aureus assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID472620Inhibition of human DHFR after 2 mins2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID289694Antibacterial activity against Pasteurella multocida at40 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID1188551Antimicrobial activity against Pseudomonas aeruginosa assessed as inhibition of visible growth after 24 hrs by disc-diffusion method2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID472622Antibacterial activity against Staphylococcus aureus after 24 hrs by microdilution susceptibility method2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID25814pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID289692Antibacterial activity against Pasteurella multocida at 20 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID743586Inhibition of bovine DHFR after 2 mins by spectrophotometry2013European journal of medicinal chemistry, May, Volume: 63Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1799602In Vitro Inhibtion Assay from Article 10.1111/j.1747-0285.2010.01036.x: \\An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.\\2010Chemical biology & drug design, Dec, Volume: 76, Issue:6
An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (363)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990235 (64.74)18.7374
1990's25 (6.89)18.2507
2000's40 (11.02)29.6817
2010's50 (13.77)24.3611
2020's13 (3.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.20 (24.57)
Research Supply Index6.03 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index125.17 (26.88)
Search Engine Supply Index2.36 (0.95)

This Compound (62.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials25 (6.44%)5.53%
Reviews0 (0.00%)6.00%
Reviews15 (3.87%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies39 (10.05%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
Other309 (79.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction [NCT02256969]Phase 445 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02256969 (4) [back to overview]Corneal Fluorescein Staining (CFS)
NCT02256969 (4) [back to overview]Ocular Surface Disease Index (OSDI)
NCT02256969 (4) [back to overview]Symptom Assessment in Dry Eye (SANDE)
NCT02256969 (4) [back to overview]Tear Break Up Time (TBUT)

Corneal Fluorescein Staining (CFS)

Is used to assess the level of corneal epitheliopathy that is related to dry eye disease. The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of epitheliopathy. (NCT02256969)
Timeframe: 4 week Time Point

Interventionunits on a scale (Mean)
Meibomian Gland Probing Plus Lubricant2.4
Sham Meibomian Gland Probing Plus Lubricant2.0
Meibomian Gland Probing Plus Blephamide1.4

[back to top]

Ocular Surface Disease Index (OSDI)

A 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms. (NCT02256969)
Timeframe: 4 week Time Point

Interventionunits on a scale (Mean)
Meibomian Gland Probing Plus Lubricant38.7
Sham Meibomian Gland Probing Plus Lubricant36.9
Meibomian Gland Probing Plus Blephamide37.3

[back to top]

Symptom Assessment in Dry Eye (SANDE)

A two-item survey used to assess the frequency and severity of dry eye disease. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms. (NCT02256969)
Timeframe: 4 week Time Point

Interventionunits on a scale (Mean)
Meibomian Gland Probing Plus Lubricant49.1
Sham Meibomian Gland Probing Plus Lubricant50.2
Meibomian Gland Probing Plus Blephamide47.6

[back to top]

Tear Break Up Time (TBUT)

TBUT measures the amount of time, in seconds, a dry spot appears in the tear film after each blink. Values less than 10 seconds are considered abnormal. (NCT02256969)
Timeframe: 4 week Time Point

InterventionSeconds (Mean)
Meibomian Gland Probing Plus Lubricant3.5
Sham Meibomian Gland Probing Plus Lubricant4.2
Meibomian Gland Probing Plus Blephamide3.2

[back to top]